This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (27) Citing Articles via Google Scholar Google Scholar Articles by Kalay, N. Articles by Ergin, A. Search for Related Content PubMed Articles by Kalay, N. Articles by Ergin, A.

Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy

Nihat Kalay, MD^_*,_*, Emrullah Basar, MD^_*, Ibrahim Ozdogru, MD^_*, Ozlem Er, MD, Yakup Cetinkaya, MD^_*, Ali Dogan, MD^_*, Tugrul Inanc, MD, Abdurrahman Oguzhan, MD^_*, Namik Kemal Eryol, MD^_*, Ramazan Topsakal, MD^_* and Ali Ergin, MD^_*

^_* Department of Cardiology, Erciyes University School of Medicine, Kayseri, Turkey
Department of Oncology, Erciyes University School of Medicine, Kayseri, Turkey.

View larger version (15K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Comparison of left ventricular ejection fraction (EF) at baseline (black bars) and after chemotherapy (white bars) in the 2 groups. Data expressed as mean values.

View larger version (13K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Individual systolic function data at baseline and after chemotherapy (CT) in the 2 groups. *p < 0.001; p = 0.3. EF = ejection fraction.

View larger version (21K): [in this window] [in a new window] [Download PPT slide]   Figure 3 Individual change in mitral early/late diastolic flow (E/A) ratio before and after chemotherapy (CT) in the 2 groups. *p < 0.02; p = 0.23.